Amneal Pharmaceuticals (NASDAQ:AMRX) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Amneal Pharmaceuticals (NASDAQ:AMRX) released its earnings results on Thursday. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.03, Zacks reports. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. Amneal Pharmaceuticals updated its FY 2026 guidance to 0.960-1.060 EPS.

Here are the key takeaways from Amneal Pharmaceuticals’ conference call:

• Q2 results exceeded expectations and full-year guidance was raised. Revenue rose 10% to $796 million, adjusted EBITDA increased 12% to $206 million, and adjusted EPS grew 20% to $0.30. Amneal raised 2026 revenue guidance to $3.1–$3.2 billion, adjusted EBITDA guidance to $750–$780 million, and EPS guidance to $0.96–$1.06.
• The pending Kashiv acquisition is expected to create a fully integrated biosimilars platform, with more than 20 programs and potential launches including Xolair, Orencia, Cimzia, and Stelara. Management expects $400–$500 million of financial benefits from tax incentives and elimination of milestone and profit-sharing obligations, with net leverage targeted below three times by 2028.
• Specialty products continued to gain traction, with specialty revenue up 17% to $149 million. CREXONT prescriptions are increasingly coming from general neurologists, while positive Phase IV data could support management’s goal of making it a first-line Parkinson’s treatment; Brekiya also reported strong early uptake.
• Complex generics and manufacturing demand remain strong, particularly for estrogen and lidocaine patches, ophthalmics, injectables, and iohexol. Amneal expects to triple estrogen-patch capacity by next year, views iohexol as a potential $50-plus million opportunity, and anticipates a meaningful contribution beginning in 2027 from recent and expected launches such as lanreotide and lenalidomide.
• Flooding at an Amneal facility in Gujarat, India is expected to temporarily disrupt a select number of products and reduce 2026 EBITDA by approximately $20 million, although operations are expected to resume within several weeks. The company also increased 2026 capital-expenditure guidance to $140–$180 million to fund capacity expansions.

Amneal Pharmaceuticals Trading Down 4.2%

Shares of AMRX traded down $0.80 during midday trading on Thursday, reaching $18.30. 1,656,820 shares of the company were exchanged, compared to its average volume of 2,174,549. Amneal Pharmaceuticals has a 1-year low of $7.66 and a 1-year high of $19.26. The stock has a 50-day moving average price of $15.99 and a 200-day moving average price of $14.19. The company has a market cap of $5.84 billion, a price-to-earnings ratio of 48.09 and a beta of 1.26.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on AMRX shares. Barclays boosted their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. UBS Group lifted their price target on shares of Amneal Pharmaceuticals from $19.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Zacks Research cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Weiss Ratings lowered shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, May 26th. Finally, Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.60.

Insiders Place Their Bets

In related news, Director Deborah M. Autor sold 34,819 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the transaction, the director owned 93,660 shares in the company, valued at approximately $1,211,960.40. The trade was a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 17.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Kemnay Advisory Services Inc. acquired a new stake in shares of Amneal Pharmaceuticals in the fourth quarter valued at $26,000. Federated Hermes Inc. boosted its stake in shares of Amneal Pharmaceuticals by 1,680.6% during the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock valued at $29,000 after buying an additional 2,168 shares during the period. Comerica Bank grew its stake in shares of Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after buying an additional 1,957 shares in the last quarter. Transamerica Financial Advisors LLC increased its position in Amneal Pharmaceuticals by 541.9% during the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after buying an additional 2,460 shares during the last quarter. Finally, Focus Partners Wealth bought a new position in Amneal Pharmaceuticals during the third quarter valued at about $42,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.